Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on January 21, 2016. The report addresses a regulatory notice received from Nasdaq regarding the Company's stock listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on listing compliance issues rather than financial performance data.
Material Changes
The Company received notice from Nasdaq that its stock failed to maintain a minimum bid price of $1.00 for 30 consecutive trading days (December 7, 2015, through January 20, 2016). Consequently, the stock is not in compliance with Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq rules grant the Company 180 calendar days to regain compliance.
- Compliance Requirement: To regain compliance, the bid price must be at least $1.00 for 10 consecutive business days within the 180-day period.
- Proposed Action: The Company previously filed a definitive proxy statement on January 7, 2016, seeking stockholder approval for a reverse stock split, which management anticipates will enable the Company to regain compliance.
Key Facts for Investor Verification
- Verify the status of the stockholder vote on the proposed reverse stock split.
- Monitor the daily bid price of the stock to ensure it meets the $1.00 threshold for 10 consecutive business days.
- Confirm the specific terms of the reverse split (ratio) once approved by stockholders.
- Check for any subsequent filings regarding the Company's progress toward Nasdaq compliance within the 180-day window.